Chris Haggard
Co-Founder & Chief Technical Officer Axiom Therapeutics
Chris Haggard is the CTO and Co-Founder of Axiom Therapeutics, where he leads the development of a machine learning–accelerated physics platform for the discovery and design of covalent inhibitors. He earned a PhD in Theoretical Chemistry from the University of Cambridge, with a focus on quantum chemistry and molecular modelling.
Seminars
Thursday 22nd October 2026
Accelerating Covalent Drug Design by Improving Prediction of Binding Reactivity & Reducing Experimental Iteration Through Physics-Based & Data-Driven Models
12:00 pm
- Assessing strengths and limitations of QM informed, physics based and ML driven approaches for modelling covalent systems
- Comparing predictive performance for reaction feasibility, binding geometry and adduct stability
- Integrating computational predictions with experimental validation to reduce synthesis burden and cycle time
